Our Story
Recordati established rare diseases operations in the Nordic and Baltic regions in 2007 as part of Recordati Rare Diseases. In 2018 the Recordati Speciality and Primary Care business unit was incorporated together with the Rare Disease business unit in Recordati AB. Today Recordati AB operates across the Nordic and Baltic regions from our regional office in Stockholm, Sweden.
Our Story
Recordati was established in the Nordic and Baltic regions with the rare diseases portfolio in 2007 due to the acquisition of Orphan Europe. In 2018 the Recordati Speciality and Primary Care business unit was incorporated together with the Rare Disease business unit in Recordati AB. Today Recordati AB operates across the Nordic and Baltic regions from our regional office in Stockholm, Sweden.
Recordati will bring treatment options across specialty and primary care and rare diseases business units, and has operations worldwide, including here in the Nordics-Baltics with a well-diversified portfolio of prescription drugs, available to healthcare professionals and patients, and offered in most Nordics-Baltics markets.
Our purpose and corporate philosophy is to give people the opportunity to unlock the full potential of life and to bring a brighter future to patients across the world.
We believe that health, and the opportunity to live life to the fullest, is a right, not a privilege.
Specialty and Primary care Nordics focuses mainly on the following therapeutical areas: cardiovascular, central nervous system, gastrointestinal, urological.
Recordati is a global international pharmaceutical company, Headquartered in Milan, Italy and listed on the Italian stock exchange. With over 4,450 employees, we develop and commercialise medicines to serve people living with common diseases, as well as those living with some of the rarest, in around 150 countries.
The Nordics-Baltics headquarter operates from Stockholm and consists of 24 employees within commercial, medical, finance, supply chain, regulatory and QA.
Focused on the few.
The Rare Diseases business unit is focused on providing the most effective treatment for unmet medical needs, mainly of genetic origin and caused by metabolic disorders, endocrine diseases, rare oncology pathologies.
Underpinned by a history of strong financial delivery, we will continue to grow from within, capture opportunities within our own pipeline, and identify opportunities to bring in new treatments through partnerships & acquisitions across all our businesses.
